查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984210

腫瘤精準醫療市場：依產品類型、技術、生物標記類型、癌症類型和最終用戶分類－2026年至2032年全球市場預測

Oncology Precision Medicine Market by Product Type, Technology, Biomarker Type, Cancer Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腫瘤精準醫療市場價值將達到 28.1 億美元，到 2026 年將成長至 30 億美元，到 2032 年將達到 44.2 億美元，複合年成長率為 6.68%。

主要市場統計數據
基準年 2025 28.1億美元
預計年份：2026年 30億美元
預測年份 2032 44.2億美元
複合年成長率 (%) 6.68%

本策略性導論探討了診斷技術的創新、治療方法的進步和數據整合如何共同作用，重新定義精準腫瘤學的臨床路徑和商業性方法。

精準腫瘤學正處於轉折點，治療方法、診斷和數據分析領域的進步正在融合，重塑臨床決策和商業策略。免疫療法、標靶治療和分子診斷領域的最新創新，正促使人們將關注點從統一的治療方案轉向更加分層的患者診療路徑，這就需要建立新的循證醫學模型，並加強包括臨床醫生、監管機構和支付方在內的各相關人員之間的合作。

治療方法的進步、診斷複雜性的增加以及支付方期望的改變，迫使癌症治療的開發和實施的整個過程採用綜合性的策略方法。

精準腫瘤學領域正經歷一場變革，其驅動力包括技術成熟、監管進步以及相關人員期望的轉變。 CAR-T細胞療法和查核點抑制劑等免疫療法正從新興療法發展成為治療流程中不可或缺的組成部分，重新​​定義了骨髓惡性腫瘤和某些固體癌的治療結果。同時，以單株抗體和小分子抑制劑形式給藥的標靶治療，也透過標靶檢驗和改進抗藥性管理策略，不斷拓展其治療範圍。

評估新關稅政策對精準腫瘤學供應鏈、檢查室運作和臨床專案韌性的營運和策略影響。

2025年新關稅政策的實施將進一步增加整個精準腫瘤學生態系統的運作複雜性，影響試劑、儀器組件和生物製藥生產投入品的供應鏈。單株抗體、細胞治療材料和定序平台的生產商將面臨某些進口原料和儀器組件接收成本增加的問題，迫使他們重新評估籌資策略和庫存管理實踐。

主導細分市場，明確治療領域、癌症類型、診斷技術、生物標記分類和最終用戶採用率，從而指南優先排序。

基於細分市場的細緻觀點能夠清楚闡明價值創造點和營運重點所在。就治療方法類型而言，荷爾蒙療法仍然是多種治療途徑的基礎；免疫療法涵蓋細胞療法，例如CAR-T細胞療法和全身性查核點抑制劑；標靶治療則包括單株抗體和小分子抑制劑。每種療法類別都有其獨特的研發、生產和商業化考量，這些都會影響跨部門規劃。

區域比較分析突顯了主要地區在採用率、報銷制度和基礎設施方面的差異如何推動了差異化的精準腫瘤學策略。

區域趨勢影響整個精準腫瘤學生態系統的應用模式和策略重點。在美洲，創新中心和完善的臨床基礎設施支持先進治療方法和全面基因組分析的快速應用。然而，支付方環境和報銷途徑的差異，使得針對不同國家和地區市場制定有針對性的證據計劃和支付方溝通策略成為必要。

關鍵參與者之間的策略聯盟、平台投資和垂直整合如何重塑精準腫瘤學領域的競爭動態和價值創造。

治療、診斷和綜合服務領域的主要企業正透過策略聯盟、平台投資和垂直整合重塑競爭動態。生物製藥公司正日益與診斷開發公司合作，共同設計伴隨檢測和並行證據生成項目，以支持監管申報和與支付方的溝通。診斷實驗室和儀器製造商正投資於自動化和數位化報告，以擴大高度複雜檢測的規模，同時提高重複性和反應速度。

為領導者提供實際有效的建議，以整合診斷開發、供應彈性和證據生成，從而加速採用和獲得支付方的認可。

產業領導者應採取果斷措施，協調臨床開發、診斷策略和商業性部署，確保治療方法的進步能持續造福患者，並帶來永續的商業成果。優先事項包括在治療方法生命週期的早期階段就納入伴隨診斷的開發，以降低監管風險，並為支付方和醫療服務提供者提供更清晰的價值提案。領導者應透過供應商多元化、盡可能採用雙重採購以及對區域製造能力進行策略性投資來增強供應鏈的韌性。

結合專家訪談、監管和臨床證據審查以及情境分析，採用穩健的多方面調查方法，提供實用見解。

本綜述的背景研究採用多種方法，旨在捕捉精準腫瘤學整體的技術、臨床、監管和營運趨勢。透過對臨床意見領袖、檢查室管理人員和供應鏈高管進行訪談，我們獲得了關於檢測實施和治療方法開發中實際操作情況的定性見解。我們將這些一線觀點與官方監管決策、同行評審的臨床文獻和技術產品文件進行交叉比對，以確保其符合當前的臨床和技術標準。

強調診斷、治療開發和彈性運作的整合，並整合策略結論，以確保永續的患者療效和商業性成功。

總之，精準腫瘤學正邁入一個以整合診斷、治療方法特異性策略和對真實世界數據日益成長的需求為特徵的新時代。免疫療法、標靶治療和先進診斷平台的相互作用正迫使相關人員重新思考研發模式、商業模式和營運基礎設施。那些能夠將伴隨診斷研發與治療方案同步、建立穩健的供應鏈網路並投資於可互通數據系統的機構，將更有能力將科學進步轉化為持續的臨床獲益。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 腫瘤精準醫療市場：依產品類型分類

  • 診斷
  • 治療
    • 荷爾蒙療法
    • 細胞和基因治療
    • 免疫療法
  • 抑制劑
  • 單株抗體

第9章 腫瘤精準醫療市場：依技術分類

  • FISH
  • IHC
  • 次世代定序
  • PCR

第10章：依生物標記類型分類的腫瘤精準醫療市場

  • 表觀遺傳學檢測
  • 基因檢測
  • 蛋白質檢測

第11章：以癌症類型分類的腫瘤精準醫療市場

  • 乳癌
  • 結腸癌
  • 肺癌
  • 惡性黑色素瘤
  • 攝護腺癌

第12章 腫瘤精準醫療市場：依最終用戶分類

  • 門診部
  • 診所
  • 診斷檢查室
  • 醫院

第13章 腫瘤精準醫療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 腫瘤精準醫療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 腫瘤精準醫療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國腫瘤精準醫療市場

第17章：中國腫瘤精準醫療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • AstraZeneca PLC
  • BJ Madan & Co.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cepheid Inc.
  • Eli Lilly & Company
  • F. Hoffmann-La Roche Ltd
  • Genome Medical boasts
  • GSK PLC
  • IQVIA Inc.
  • Laboratory Corporation Of America Holding
  • llumina, Inc.
  • Merck KGaA
  • Novartis AG
  • OneOme, LLC
  • Pfizer Inc.
  • Rain Oncology Inc.
  • Relay Therapeutics
  • Sanofi SA
  • Strata Oncology, Inc.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific, Inc.
  • Variantyx, Inc.
  • Xilis, Inc.
Product Code: MRR-5C6F41F5B030

The Oncology Precision Medicine Market was valued at USD 2.81 billion in 2025 and is projected to grow to USD 3.00 billion in 2026, with a CAGR of 6.68%, reaching USD 4.42 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.81 billion
Estimated Year [2026] USD 3.00 billion
Forecast Year [2032] USD 4.42 billion
CAGR (%) 6.68%

A strategic primer introducing how diagnostic innovation, therapeutic evolution, and data integration are jointly redefining precision oncology clinical pathways and commercial approaches

Precision oncology stands at an inflection point as converging advances in therapeutics, diagnostics, and data analytics reshape clinical decision making and commercial strategy. Recent innovations in immunotherapy modalities, targeted agents, and molecular diagnostics have shifted the emphasis from one-size-fits-all approaches to finely stratified patient care pathways, demanding new evidence-generation models and closer alignment across clinical, regulatory, and payer stakeholders.

This introduction synthesizes the principal drivers of change, outlines the practical implications for developers and providers, and frames the subsequent sections that probe structural shifts, tariff-related supply chain risks, and segmentation-specific dynamics. Stakeholders face accelerating complexity: multiplex assays and next-generation sequencing outputs are informing therapy selection in real time, and companion diagnostic pairing is increasingly integral to clinical trial design and product positioning.

Moreover, as care delivery becomes more decentralized, diagnostic laboratories and ambulatory settings are adopting technologies that were once confined to tertiary centers. Transitioning from proof-of-concept to scalable implementation requires integrated operational plans, cross-functional collaboration, and investment in data interoperability. The subsequent analysis highlights where organizational focus is most likely to yield durable clinical and commercial advantage.

How converging therapeutic advances, diagnostic multiplexing, and evolving payer expectations are forcing integrated strategic approaches across oncology development and delivery

The landscape of precision oncology is undergoing transformative shifts driven by technological maturation, regulatory evolution, and changing stakeholder expectations. Immunotherapies such as CAR T-cell interventions and checkpoint inhibitors have moved from novelty to essential components of treatment algorithms, redefining outcomes in hematologic malignancies and selected solid tumors. Concurrently, targeted therapies delivered as monoclonal antibodies or small molecule inhibitors continue to refine therapeutic windows through improved target validation and resistance management strategies.

Diagnostics have evolved from single-analyte tests to multiplexed platforms; immunohistochemistry and fluorescence in situ hybridization remain foundational, while polymerase chain reaction assays and next-generation sequencing now enable broader genomic profiling at clinically actionable depth. This diagnostic breadth supports more precise stratification across common cancer types, allowing clinicians to match interventions to tumor biology with greater confidence.

Commercially, payers and health systems are demanding stronger evidence of clinical utility and real-world benefit, prompting sponsors to design adaptive trial frameworks and post-approval evidence programs. Partnerships between diagnostics providers and pharmaceutical developers are expanding, with co-development and bundled reimbursement models gaining traction. Taken together, these shifts elevate the importance of integrated clinical development strategies that anticipate regulatory expectations and delivery system constraints.

Assessing the operational and strategic consequences of new tariff policies on supply chains, laboratory operations, and clinical program resilience across precision oncology

The introduction of new tariff policies in 2025 has introduced additional layers of operational complexity across the precision oncology ecosystem, affecting supply chains for reagents, instrument components, and biologic production inputs. Manufacturers of monoclonal antibodies, cell-therapy materials, and sequencing platforms face higher landed costs for certain imported raw materials and instrument subassemblies, prompting reassessments of sourcing strategies and inventory practices.

These tariff-related pressures have ripple effects through clinical development and laboratory operations. Diagnostic laboratories reliant on imported consumables may encounter longer procurement lead times and greater cost volatility, which can complicate assay standardization and laboratory accreditation timelines. Clinical trial sponsors operating global studies must now account for variable local costs and potential disruptions to investigational product supply, influencing site selection and trial logistics.

In response, organizations are intensifying efforts to diversify supplier bases, prioritize domestic manufacturing partnerships where feasible, and redesign packaging and shipment practices to reduce exposure to tariff-sensitive categories. Regulatory submissions and quality programs must incorporate contingency planning for supplier substitutions, and contracting teams are negotiating more flexible terms with vendors. While tariffs present material execution risks, they are also accelerating investments in regionalized manufacturing capacity and robust supply network mapping to preserve continuity in both therapeutic and diagnostic delivery.

Segmentation-driven insights that delineate therapeutic categories, cancer types, diagnostic technologies, biomarker classes, and end-user deployment realities to guide prioritization

A careful segmentation-driven lens clarifies where value is created and where operational attention is required. When considering therapy type, hormonal treatments continue to anchor several care pathways, immunotherapies encompass both cellular approaches such as CAR T-cell therapy and systemic checkpoint inhibitors, and targeted therapy spans monoclonal antibodies as well as small molecule inhibitors; each therapeutic category carries distinct development, manufacturing, and commercialization considerations that influence cross-functional planning.

Cancer-type segmentation highlights the divergent clinical and diagnostic needs across disease areas: breast cancer, colorectal cancer, lung cancer, melanoma, and prostate cancer each present unique biomarker landscapes, differing standard-of-care backdrops, and variable payer willingness to reimburse advanced diagnostics and combination regimens. Tailoring clinical evidence strategies to the natural history and treatment paradigms of each tumor type enhances the relevance of diagnostic-therapeutic pairings.

Technology segmentation separates the methodological approaches that underpin contemporary diagnostics, including fluorescence in situ hybridization, immunohistochemistry, next-generation sequencing, and polymerase chain reaction. Each technology offers trade-offs across sensitivity, throughput, turnaround time, and operational footprint, influencing which settings can realistically adopt them. Biomarker-type segmentation-covering epigenetic testing, genetic testing, and protein testing-further refines where assays will impact treatment decisions and regulatory pathways.

End-user segmentation clarifies deployment and commercialization pathways: ambulatory care centers, clinics, diagnostic laboratories, and hospitals differ in capital capacity, workflow integration capability, and reimbursement coding practices. Aligning product design and service models to the operational realities of these end users supports faster adoption and smoother implementation. Collectively, this layered segmentation approach supports more precise prioritization of investment, evidence generation, and go-to-market sequencing.

Comparative regional analysis highlighting how adoption, reimbursement, and infrastructure differences across major geographies drive differentiated precision oncology strategies

Regional dynamics are shaping both adoption patterns and strategic priorities across the precision oncology ecosystem. In the Americas, innovation hubs and extensive clinical infrastructure support rapid uptake of advanced therapeutics and comprehensive genomic profiling, yet divergent payer environments and reimbursement pathways require targeted evidence planning and payer engagement strategies tailored to national and subnational markets.

Within Europe, the Middle East & Africa, heterogeneous regulatory landscapes and variable access to specialized care influence how diagnostics and novel therapies are introduced. Centralized health technology assessment mechanisms in parts of Europe emphasize comparative effectiveness and cost-effectiveness, while select markets in the Middle East are building capacity for advanced cell therapies and precision diagnostics. In parts of Africa, constrained laboratory infrastructure and supply chain fragility necessitate tailored models for decentralized testing and durable reagent supply.

The Asia-Pacific region presents a spectrum of mature metropolitan centers alongside rapidly developing healthcare systems. High-throughput sequencing adoption and investments in domestic biologics manufacturing are notable in several markets, creating opportunities for regional supply partnerships and localized clinical development. At the same time, regulatory harmonization and variable reimbursement criteria require flexible access strategies that can accelerate patient access while meeting local evidence requirements. Across regions, stakeholders must reconcile global product strategies with nuanced local operational and regulatory realities.

How strategic alliances, platform investments, and vertical integration among leading players are reshaping competitive dynamics and value capture in precision oncology

Leading organizations in therapeutics, diagnostics, and integrated service provision are reshaping competitive dynamics through strategic alliances, platform investments, and vertical integration. Biopharmaceutical sponsors are increasingly collaborating with diagnostic developers to co-design companion assays and parallel evidence-generation programs that support regulatory filings and payer conversations. Diagnostic laboratories and instrument providers are investing in automation and digital reporting to scale high-complexity testing while improving reproducibility and turnaround times.

Supply chain partners and contract manufacturers are expanding capabilities in cell-therapy support services and biologics fill-finish operations to meet rising demand for complex modalities. Technology companies are deploying cloud-based analytics and machine learning to enhance variant interpretation and to create clinician-facing decision support tools that translate sequencing outputs into actionable insights. These moves are influencing strategic partnerships, M&A activity, and the formation of preferred supplier networks.

Across the ecosystem, firms that can demonstrate end-to-end value-linking robust analytical validity, clinical utility, and practical implementation support-are positioned to secure stronger adoption in provider networks and to engage more effectively with payers. Operational excellence in manufacturing, regulatory acumen, and the capacity to deliver real-world evidence will distinguish leaders from followers in the near to medium term.

Practical and high-impact recommendations for leaders to integrate diagnostic-development, supply resilience, and evidence generation to accelerate adoption and payer acceptance

Industry leaders should take decisive steps to align clinical development, diagnostic strategy, and commercial implementation so that therapeutic advances translate into durable patient benefit and sustainable business outcomes. Priorities include embedding companion diagnostic development early in the therapeutic lifecycle to de-risk regulatory pathways and to create clearer value propositions for payers and providers. Leaders should reinforce supply chain resilience through supplier diversification, dual sourcing where feasible, and strategic investments in regional manufacturing capabilities.

Operationally, organizations must invest in interoperable data platforms and evidence-generation frameworks that support rapid accumulation of real-world outcomes. Strengthening collaborations with diagnostic laboratories and care delivery settings will accelerate adoption, particularly when implementation workflows and reimbursement pathways are clearly addressed. In parallel, commercial teams should develop tailored health-economic narratives that reflect the specific clinical contexts of each cancer type and the diagnostic technologies employed.

Finally, fostering cross-functional governance that integrates regulatory, clinical, commercial, and supply chain decision-making will reduce time-to-adoption risks and improve alignment across launch and post-launch activities. By prioritizing these actions, leaders will be better positioned to navigate regulatory complexity, payer scrutiny, and operational disruption while delivering measurable improvements in patient care.

Robust multi-method research methodology combining expert interviews, regulatory and clinical evidence review, and scenario analysis to underpin actionable insights

The research behind this synthesis integrates a multi-method approach to capture technological, clinical, regulatory, and operational developments across precision oncology. Primary interviews with clinical thought leaders, laboratory directors, and supply chain executives provided qualitative insights into the operational realities of assay implementation and therapeutic deployment. These firsthand perspectives were triangulated with public regulatory decisions, peer-reviewed clinical literature, and technical product documentation to ensure alignment with the latest clinical and technological standards.

Secondary analysis of diagnostic workflows, technology adoption case studies, and payer policy statements informed the assessment of deployment constraints and reimbursement drivers. Scenario analysis was applied to stress-test supply chain vulnerabilities and to identify pragmatic mitigation steps that organizations are currently implementing. The methodology emphasizes transparency in source attribution and conservative interpretation of qualitative inputs, focusing on observable trends and documented policy shifts rather than speculative projections.

Throughout the research process, efforts were made to corroborate findings across multiple stakeholders and to surface divergent perspectives where consensus is lacking. This mixed-methods framework is intended to provide decision-makers with a balanced, actionable view of the strategic and operational choices that will shape precision oncology over the near term.

Synthesis of strategic conclusions emphasizing integration of diagnostics, therapy development, and resilient operations to secure durable patient and commercial outcomes

In conclusion, precision oncology is transitioning into an era defined by integrated diagnostics, modality-specific therapeutic strategies, and heightened expectations for real-world evidence. The interplay between immunotherapies, targeted agents, and advanced diagnostic platforms is prompting stakeholders to rethink development paradigms, commercial models, and operational infrastructure. Organizations that synchronize companion diagnostic development with therapeutic programs, build resilient supply networks, and invest in interoperable data systems will be better equipped to translate scientific advances into consistent clinical benefit.

Tariff-related supply risks and varied regional access environments underscore the need for flexible, regionally informed strategies. By prioritizing cross-functional governance and early payer engagement, sponsors and service providers can mitigate adoption barriers and accelerate the translation of innovations into standard practice. The path forward favors those who combine scientific rigor with pragmatic operational design, ensuring that promising therapies reach the right patients efficiently and sustainably.

Taken together, these conclusions provide a strategic foundation for stakeholders seeking to navigate the evolving precision oncology ecosystem with clarity and purpose.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oncology Precision Medicine Market, by Product Type

  • 8.1. Diagnostics
  • 8.2. Therepy
    • 8.2.1. Hormonal Therapy
    • 8.2.2. Cell & Gene Therapy
    • 8.2.3. Immunotherapy
  • 8.3. Inhibitor Drugs
  • 8.4. Monoclonal Antibodies

9. Oncology Precision Medicine Market, by Technology

  • 9.1. FISH
  • 9.2. IHC
  • 9.3. Next Generation Sequencing
  • 9.4. PCR

10. Oncology Precision Medicine Market, by Biomarker Type

  • 10.1. Epigenetic Testing
  • 10.2. Genetic Testing
  • 10.3. Protein Testing

11. Oncology Precision Medicine Market, by Cancer Type

  • 11.1. Breast Cancer
  • 11.2. Colorectal Cancer
  • 11.3. Lung Cancer
  • 11.4. Melanoma
  • 11.5. Prostate Cancer

12. Oncology Precision Medicine Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Clinics
  • 12.3. Diagnostic Laboratories
  • 12.4. Hospitals

13. Oncology Precision Medicine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Oncology Precision Medicine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Oncology Precision Medicine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Oncology Precision Medicine Market

17. China Oncology Precision Medicine Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. AstraZeneca PLC
  • 18.7. B. J. Madan & Co.
  • 18.8. Bayer AG
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. Cepheid Inc.
  • 18.11. Eli Lilly & Company
  • 18.12. F. Hoffmann-La Roche Ltd
  • 18.13. Genome Medical boasts
  • 18.14. GSK PLC
  • 18.15. IQVIA Inc.
  • 18.16. Laboratory Corporation Of America Holding
  • 18.17. llumina, Inc.
  • 18.18. Merck KGaA
  • 18.19. Novartis AG
  • 18.20. OneOme, LLC
  • 18.21. Pfizer Inc.
  • 18.22. Rain Oncology Inc.
  • 18.23. Relay Therapeutics
  • 18.24. Sanofi S.A.
  • 18.25. Strata Oncology, Inc.
  • 18.26. Takeda Pharmaceutical Company Limited
  • 18.27. Thermo Fisher Scientific, Inc.
  • 18.28. Variantyx, Inc.
  • 18.29. Xilis, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CELL & GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CELL & GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY INHIBITOR DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY INHIBITOR DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY INHIBITOR DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY FISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY FISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY FISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IHC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IHC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IHC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY EPIGENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY EPIGENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY EPIGENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROTEIN TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROTEIN TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROTEIN TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. GCC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GCC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. GCC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 145. GCC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. GCC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. G7 ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. G7 ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. G7 ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 166. G7 ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. G7 ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. G7 ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. G7 ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. NATO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. NATO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. NATO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. NATO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. NATO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)